![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 23, 2007 8:13:53 AM
Nexavar should get an average of almost $50,000 per patient for liver cancer in the U.S. There are an estimated 19,000 deaths per year in the U.S., over 30,000 deaths per year in Europe, over 40,000 deaths per year in Japan, and well over 300,000 deaths per year in Asia.
ONXX has about 55 million shares outstanding and a partnership with Bayer for Nexavar. ONXX splits U.S. profits 50/50, gets a lower profit percentage from the rest of the world ex-Japan but does not share in the expenses, and will receive a royalty from Japanese sales.
With Nexavar already on the market in the U.S. and Europe for kidney cancer, doctors are writing prescriptions for Nexavar for liver cancer right now.
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM